Sort   by:  
 Page size 
UnknownDeep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.
Not available
S-EPMC10694617 | biostudies-literature
UnknownXBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.
Not available
S-EPMC10948033 | biostudies-literature
UnknownKP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2.
Not available
S-EPMC12181982 | biostudies-literature
UnknownCabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Not available
S-EPMC4110249 | biostudies-literature
UnknownRobust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.
Not available
S-EPMC11524932 | biostudies-literature
UnknownVariant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections.
Not available
S-EPMC12639126 | biostudies-literature
UnknownAntibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC.
Not available
S-EPMC12014523 | biostudies-literature
UnknownAntibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants.
Not available
S-EPMC12723667 | biostudies-literature
UnknownSARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.
Not available
S-EPMC10058662 | biostudies-literature
UnknownVariant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic overall infections.
Not available
S-EPMC11844606 | biostudies-literature
Sort   by:  
 Page size